Top

Published in:

01-03-2020 | Cardiomyopathy

Cardiovascular diseases in survivors of childhood cancer

Authors: Neha Bansal, Javier G. Blanco, Umesh C. Sharma, Saraswati Pokharel, Shannon Shisler, Steven E. Lipshultz

Published in: Cancer and Metastasis Reviews | Issue 1/2020

Abstract

Over the past few decades, the diagnosis and management of children with various malignancies have improved tremendously. As a result, there are an increasing number of children who are long-term cancer survivors. With improved survival, however, has come an increased risk of treatment-related cardiovascular complications that can appear decades after treatment. These problems are serious enough that all caregivers of childhood cancer survivors, including oncologists, cardiologists, and other health care personnel, must pay close attention to the short- and long-term effects of chemotherapy and radiotherapy on these children. This review discusses the effects of treatment-related cardiovascular complications from anthracyclines and radiotherapy and the methods for preventing, screening, and treating these complications.

Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians, 66(4), 271–289.

Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007). Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy, 8(8), 1039–1058.CrossRefPubMed

Siegel, R. L., Miller, K. D., Jemal, A., & Cancer statistics. (2015). CA: a Cancer Journal for Clinicians, 65(1), 5–29.

Scully, R. E., & Lipshultz, S. E. (2007). Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology, 7(2), 122–128.CrossRefPubMed

Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., et al. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ., 339, b4606.CrossRefPubMedPubMedCentral

Mertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008). Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 100(19), 1368–1379.CrossRefPubMedPubMedCentral

Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., Robison, L. L., & Childhood Cancer Survivor Study. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355(15), 1572–1582.CrossRefPubMed

Lipshultz, S. E., & Adams, M. J. (2010). Cardiotoxicity after childhood cancer: beginning with the end in mind. Journal of Clinical Oncology, 28(8), 1276–1281.CrossRefPubMed

Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., Winter, D., Bourhis, J., Lefkopoulos, D., Diallo, I., & de Vathaire, F. (2010). Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. Journal of Clinical Oncology, 28(8), 1308–1315.CrossRefPubMed

10.

Levitt, G., Anazodo, A., Burch, M., & Bunch, K. (2009). Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? European Journal of Cancer, 45(17), 3027–3034.CrossRefPubMed

11.

Valcovici, M., Andrica, F., Serban, C., & Dragan, S. (2016). Cardiotoxicity of anthracycline therapy: current perspectives. Archives of Medical Science, 12(2), 428–435.CrossRefPubMedPubMedCentral

12.

Nysom, K., Holm, K., Lipsitz, S. R., Mone, S. M., Colan, S. D., Orav, E. J., Sallan, S. E., Olsen, J. H., Hertz, H., Jacobsen, J. R., & Lipshultz, S. E. (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16(2), 545–550.CrossRefPubMed

13.

Chu E SA: cancer chemotherapy, 9th ed edn. New York: Lange Medical Books/McGraw-Hill 2004.

14.

Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008). Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart., 94(4), 525–533.CrossRefPubMed

15.

Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., & Gersl, V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 61(1), 154–171.CrossRefPubMed

16.

De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2010). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation., 121(2), 276–292.CrossRefPubMed

17.

Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234–235(1–2), 119–124.CrossRefPubMed

18.

Jurcut, R., Wildiers, H., Ganame, J., D'Hooge, J., Paridaens, R., & Voigt, J. U. (2008). Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Supportive Care in Cancer, 16(5), 437–445.CrossRefPubMed

19.

Rusconi, P., Gomez-Marin, O., Rossique-Gonzalez, M., Redha, E., Marin, J. R., Lon-Young, M., et al. (2004). Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation, 23(7), 832–838.CrossRefPubMed

20.

Lowis, S., Lewis, I., Elsworth, A., Weston, C., Doz, F., Vassal, G., Bellott, R., Robert, J., Pein, F., Ablett, S., Pinkerton, R., Frappaz, D., United Kingdom Children’s Cancer Study Group (UKCCSG) New Agents, & Société Française d’Oncologie Pédiatrique (SFOP) Pharmacology Group. (2006). A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British Journal of Cancer, 95(5), 571–580.CrossRefPubMedPubMedCentral

21.

Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., & Walker, U. A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. The Journal of Pathology, 207(4), 436–444.CrossRefPubMed

22.

Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Journal of the National Cancer Institute, 100(15), 1058–1067.CrossRefPubMed

23.

Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine, 18(11), 1639–1642.CrossRefPubMed

24.

Khiati, S., Dalla Rosa, I., Sourbier, C., Ma, X., Rao, V. A., Neckers, L. M., Zhang, H., & Pommier, Y. (2014). Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clinical Cancer Research, 20(18), 4873–4881.CrossRefPubMedPubMedCentral

25.

Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine, 324(12), 808–815.CrossRefPubMed

26.

Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332(26), 1738–1743.CrossRefPubMed

27.

Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997). Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Journal of Clinical Oncology, 15(4), 1544–1552.CrossRefPubMed

28.

Lipshultz, S. E., Karnik, R., Sambatakos, P., Franco, V. I., Ross, S. W., & Miller, T. L. (2014). Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology, 29(1), 103–112.CrossRefPubMed

29.

Rinehart, J. J., Lewis, R. P., & Balcerzak, S. P. (1974). Adriamycin cardiotoxicity in man. Annals of Internal Medicine, 81(4), 475–478.CrossRefPubMed

30.

Grenier, M. A., & Lipshultz, S. E. (1998). Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology, 25(4 Suppl 10), 72–85.PubMed

31.

Bryant, J., Picot, J., Levitt, G., Sullivan, I., Baxter, L., & Clegg, A. (2007). Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess, 11(27):iii, ix-x), 1–84.CrossRef

32.

Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voute, P. A. (2002). Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology, 13(6), 819–829.CrossRefPubMed

33.

Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., et al. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337.CrossRefPubMedPubMedCentral

34.

Wojnowski, L., Kulle, B., Schirmer, M., Schluter, G., Schmidt, A., & Rosenberger, A. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation., 112.

35.

Linschoten, M., Teske, A. J., Cramer, M. J., van der Wall, E., & Asselbergs, F. W. (2018). Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med., 11(1), e001753.CrossRefPubMed

36.

Chang, V. Y., & Wang, J. J. (2018). Pharmacogenetics of chemotherapy-induced cardiotoxicity. Current Oncology Reports, 20(7), 52.CrossRefPubMedPubMedCentral

37.

Aminkeng, F., Ross, C. J., Rassekh, S. R., Hwang, S., Rieder, M. J., Bhavsar, A. P., Smith, A., Sanatani, S., Gelmon, K. A., Bernstein, D., Hayden, M. R., Amstutz, U., Carleton, B. C., & CPNDS Clinical Practice Recommendations Group. (2016). Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. British Journal of Clinical Pharmacology, 82(3), 683–695.CrossRefPubMedPubMedCentral

38.

Magdy, T., Burmeister, B. T., & Burridge, P. W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacology & Therapeutics, 168, 113–125.CrossRef

39.

Leong, S. L., Chaiyakunapruk, N., & Lee, S. W. (2017). Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis., 7(1), 39.

40.

Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I., Davies, S. M., Relling, M. V., Robison, L. L., Sklar, C. A., Stovall, M., & Bhatia, S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer., 112(12), 2789–2795.CrossRefPubMed

41.

Blanco, J. G., Sun, C. L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., Neglia, J. P., Oeffinger, K. C., Ritchey, A. K., Villaluna, D., Relling, M. V., & Bhatia, S. (2012). Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children’s Oncology Group. Journal of Clinical Oncology, 30(13), 1415–1421.CrossRefPubMed

42.

Salvatorelli, E., Menna, P., Chello, M., Covino, E., & Minotti, G. (2018). Low-dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites. The Journal of Pharmacology and Experimental Therapeutics, 364(2), 323–331.CrossRefPubMed

43.

Wang, X., Sun, C. L., Quinones-Lombrana, A., Singh, P., Landier, W., Hageman, L., et al. (2016). CELF4 variant and anthracycline-related cardiomyopathy: a Children’s Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology, 34(8), 863–870.CrossRefPubMedPubMedCentral

44.

Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B. (2013). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer., 119(19), 3555–3562.CrossRefPubMed

45.

Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of Clinical Oncology, 33(5), 394–402.CrossRefPubMed

46.

Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2009). New developments in anthracycline-induced cardiotoxicity. Current Medicinal Chemistry, 16(13), 1656–1672.CrossRefPubMed

47.

Brown, S. A., Sandhu, N., & Herrmann, J. (2015). Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature Reviews. Clinical Oncology, 12(12), 718–731.CrossRefPubMed

48.

Lenihan, D. J., Oliva, S., Chow, E. J., & Cardinale, D. (2013). Cardiac toxicity in cancer survivors. Cancer., 119, 2131–2142.CrossRefPubMed

49.

Lipshultz, S. E., Cochran, T. R., Franco, V. I., & Miller, T. L. (2013). Treatment-related cardiotoxicity in survivors of childhood cancer. Nature Reviews. Clinical Oncology, 10(12), 697–710.CrossRefPubMed

50.

Wang, X., Chen, Y., Hageman, L., Singh, P., Landier, W., Blanco, J. G., et al. (2019). Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report., 37(15_suppl), 10015–10015.

51.

Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., & Lipshultz, S. E. (1998). Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology, 27(1), 53–68.CrossRefPubMed

52.

Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., & Lipshultz, S. E. (2005). Cardiotoxicity of cancer chemotherapy: implications for children. Paediatric Drugs, 7(3), 187–202.CrossRefPubMed

53.

Adams, M. J., & Lipshultz, S. E. (2005). Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood & Cancer, 44(7), 600–606.CrossRef

54.

Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011). Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology, 32(3), 342–353.CrossRefPubMed

55.

Bristow, M. R., Mason, J. W., Billingham, M. E., & Daniels, J. R. (1978). Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Annals of Internal Medicine, 88(2), 168–175.CrossRefPubMed

56.

Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23(12), 2629–2636.CrossRefPubMed

57.

Lipshultz, S. E., Scully, R. E., Stevenson, K. E., Franco, V. I., Neuberg, D. S., Colan, S. D., et al. (2014). Hearts too small for body size after doxorubicin for childhood leukemia: Grinch syndrome. J Clin Oncol, 32, –10021 (abstr.).

58.

Wouters, K. A., Kremer, L. C., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. British Journal of Haematology, 131(5), 561–578.CrossRefPubMed

59.

Lipshultz, S. E. (1996). Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Journal of Clinical Oncology, 14(2), 328–331.CrossRefPubMed

60.

Hasinoff, B. B., & Herman, E. H. (2007). Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology, 7(2), 140–144.CrossRefPubMed

61.

Hutchins, K. K., Siddeek, H., Franco, V. I., & Lipshultz, S. E. (2017). Prevention of cardiotoxicity among survivors of childhood cancer. British Journal of Clinical Pharmacology, 83(3), 455–465.CrossRefPubMed

62.

Vejpongsa, P., & Yeh, E. T. (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938–945.CrossRefPubMed

63.

Chang, H. M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017). Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. Journal of the American College of Cardiology, 70(20), 2536–2551.CrossRefPubMedPubMedCentral

64.

Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation., 96(8), 2641–2648.CrossRefPubMed

65.

Armenian, S. H., & Ehrhardt, M. J. (2019). Optimizing cardiovascular care in children with acute myeloid leukemia to improve cancer-related outcomes. Journal of Clinical Oncology, 37(1), 1–6.CrossRefPubMed

66.

Questions and answers on cardioxane [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cardioxane/human_referral_000421.jsp&mid=WC0b01ac05805c516f].

67.

Reichardt, P., Tabone, M. D., Mora, J., Morland, B., & Jones, R. L. (2018). Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology.

68.

Lipshultz, S. E. (2018). Letter by Lipshultz regarding article, “Anthracycline cardiotoxicity: worrisome enough to have you quaking?”. Circulation Research, 122(7), e62–e63.CrossRefPubMedPubMedCentral

69.

Bansal, N., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2017). Chemotherapy-induced cardiotoxicity in children. Expert Opinion on Drug Metabolism & Toxicology, 13(8), 817–832.CrossRef

70.

Lipshultz, S. E., & Herman, E. H. (2018). Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovascular Research, 114(2), 205–209.CrossRefPubMed

71.

Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., et al. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology., 5(1), 18.CrossRefPubMedPubMedCentral

72.

Cardinale, D., Ciceri, F., Latini, R., Franzosi, M. G., Sandri, M. T., Civelli, M., Cucchi, G., Menatti, E., Mangiavacchi, M., Cavina, R., Barbieri, E., Gori, S., Colombo, A., Curigliano, G., Salvatici, M., Rizzo, A., Ghisoni, F., Bianchi, A., Falci, C., Aquilina, M., Rocca, A., Monopoli, A., Milandri, C., Rossetti, G., Bregni, M., Sicuro, M., Malossi, A., Nassiacos, D., Verusio, C., Giordano, M., Staszewsky, L., Barlera, S., Nicolis, E. B., Magnoli, M., Masson, S., Cipolla, C. M., & ICOS-ONE Study Investigators. (2018). Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. European Journal of Cancer, 94, 126–137.CrossRefPubMed

73.

Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of Clinical Oncology, 25(25), 3991–4008.CrossRefPubMed

74.

Burnett Jr., H. W., Steinberg, I., & Dotter, C. T. (1952). Seven-year survival after radiation therapy in a patient with inoperable cancer of the lung. The New England Journal of Medicine, 247(22), 850–851.CrossRefPubMed

75.

Wu, L., Pang, S., Yao, Q., Jian, C., Lin, P., Feng, F., Li, H., & Li, Y. (2017). Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. Scientific Reports, 7(1), 3471.CrossRefPubMedPubMedCentral

76.

Thames Jr., H. D., Withers, H. R., Peters, L. J., & Fletcher, G. H. (1982). Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. International Journal of Radiation Oncology, Biology, Physics, 8(2), 219–226.CrossRefPubMed

77.

Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., et al. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England Journal of Medicine, 368(11), 987–998.CrossRefPubMed

78.

Ming, X., Feng, Y., Yang, C., Wang, W., Wang, P., & Deng, J. (2016). Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update. Medicine (Baltimore), 95(41), e5051.CrossRef

79.

Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., Tate, D. J., Horning, S. J., Hoppe, R. T., & Hancock, S. L. (2007). Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. Journal of Clinical Oncology, 25(1), 43–49.CrossRefPubMed

80.

Kole, T. P., Aghayere, O., Kwah, J., Yorke, E. D., & Goodman, K. A. (2012). Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1580–1586.CrossRefPubMed

81.

Wu, W. C., Chan, C. L., Wong, Y. W., & Cuijpers, J. P. (2010). A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. The British Journal of Radiology, 83(987), 252–256.CrossRefPubMedPubMedCentral

82.

Fajardo, L. F., Eltringham, J. R., & Steward, J. R. (1976). Combined cardiotoxicity of adriamycin and x-radiation. Laboratory Investigation, 34(1), 86–96.PubMed

83.

Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., Pham, L., Chen, H. H., Burnett, J. C., Russell, S. J., & Redfield, M. M. (2017). Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. American Journal of Physiology. Heart and Circulatory Physiology, 313(2), H392–H407.CrossRefPubMedPubMedCentral

84.

Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews. Immunology, 4(8), 583–594.CrossRefPubMedPubMedCentral

85.

Schultz-Hector, S., & Trott, K. R. (2007). Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? International Journal of Radiation Oncology, Biology, Physics, 67(1), 10–18.CrossRefPubMed

86.

Yarnold, J., & Brotons, M. C. (2010). Pathogenetic mechanisms in radiation fibrosis. Radiotherapy and Oncology, 97(1), 149–161.CrossRefPubMed

87.

Stewart, J. R., & Fajardo, L. F. (1984). Radiation-induced heart disease: an update. Progress in Cardiovascular Diseases, 27(3), 173–194.CrossRefPubMed

88.

Shapiro, C. L. (2018). Cancer survivorship. The New England Journal of Medicine, 379(25), 2438–2450.CrossRefPubMed

89.

Shapiro, C. L., & Recht, A. (2001). Side effects of adjuvant treatment of breast cancer. The New England Journal of Medicine, 344(26), 1997–2008.CrossRefPubMed

90.

Loffler, A. I., & Bourque, J. M. (2016). Coronary microvascular dysfunction, microvascular angina, and management. Current Cardiology Reports, 18(1), 1.CrossRefPubMedPubMedCentral

91.

Melikian, N., De Bruyne, B., Fearon, W. F., & MacCarthy, P. A. (2008). The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Progress in Cardiovascular Diseases, 50(4), 294–310.CrossRefPubMed

92.

Seddon, B., Cook, A., Gothard, L., Salmon, E., Latus, K., Underwood, S. R., & Yarnold, J. (2002). Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiotherapy and Oncology, 64(1), 53–63.CrossRefPubMed

93.

Marinescu, M. A., Loffler, A. I., Ouellette, M., Smith, L., Kramer, C. M., & Bourque, J. M. (2015). Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC: Cardiovascular Imaging, 8(2), 210–220.PubMed

94.

Tschope, C., & Van Linthout, S. (2014). New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Current Heart Failure Reports, 11(4), 436–444.CrossRefPubMedPubMedCentral

95.

Faccini, A., Kaski, J. C., & Camici, P. G. (2016). Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. European Heart Journal, 37(23), 1799–1806.CrossRefPubMed

96.

Camici, P. G., & Crea, F. (2007). Coronary microvascular dysfunction. The New England Journal of Medicine, 356(8), 830–840.CrossRefPubMed

97.

Richardson, R. B. (2009). Ionizing radiation and aging: rejuvenating an old idea. Aging (Albany NY), 1(11), 887–902.CrossRef

98.

Baverstock, K., & Karotki, A. V. (2011). Towards a unifying theory of late stochastic effects of ionizing radiation. Mutation Research, 718(1–2), 1–9.PubMed

99.

Furth, J., Upton, A. C., Christenberry, K. W., Benedict, W. H., & Moshman, J. (1954). Some late effects in mice of ionizing radiation from an experimental nuclear detonation. Radiology., 63(4), 562–570.CrossRefPubMed

100.

Sokolova, N. V., & Gorshenina, T. I. (1959). Relation of the localization of radiation injury to functional state of the organ. 1. Biulleten’ Eksperimental’, 48, 29–34.

101.

Edwards, A. A., & Lloyd, D. C. (1998). Risks from ionising radiation: deterministic effects. Journal of Radiological Protection, 18(3), 175–183.CrossRefPubMed

102.

Huang, Y. J., Harrison, A., Sarkar, V., Rassiah-Szegedi, P., Zhao, H., Szegedi, M., Huang, L., Wilson, B., Gaffney, D. K., & Salter, B. J. (2016). Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging. Adv Radiat Oncol., 1(2), 106–114.CrossRefPubMedPubMedCentral

103.

Rubin, E., Camara, J., Grayzel, D. M., & Zak, F. G. (1963). Radiation-induced cardiac fibrosis. The American Journal of Medicine, 34, 71–75.CrossRefPubMed

104.

Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clinic Proceedings, 89(9), 1287–1306.CrossRefPubMed

105.

Cuomo, J. R., Sharma, G. K., Conger, P. D., & Weintraub, N. L. (2016). Novel concepts in radiation-induced cardiovascular disease. World Journal of Cardiology, 8(9), 504–519.CrossRefPubMedPubMedCentral

106.

Antonadou, D., Coliarakis, N., Synodinou, M., Athanassiou, H., Kouveli, A., Verigos, C., et al. (2001). Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. International Journal of Radiation Oncology, Biology, Physics, 51(4), 915–922.CrossRefPubMed

107.

Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., Mizuno, K., Ohashi, Y., & MEGA Study Group. (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet., 368(9542), 1155–1163.CrossRefPubMed

108.

Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathe, D., et al. (2007). Pravastatin inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clinical Cancer Research, 13(18 Pt 1), 5331–5340.CrossRefPubMed

109.

Holler, V., Buard, V., Gaugler, M. H., Guipaud, O., Baudelin, C., Sache, A., Perez Mdel, R., Squiban, C., Tamarat, R., Milliat, F., & Benderitter, M. (2009). Pravastatin limits radiation-induced vascular dysfunction in the skin. The Journal of Investigative Dermatology, 129(5), 1280–1291.CrossRefPubMed

110.

Dainiak, N., & Tan, B. J. (1995). Utility of biological membranes as indicators for radiation exposure: alterations in membrane structure and function over time. Stem Cells, 13(Suppl 1), 142–152.PubMed

111.

Lett, J. T. (1992). Damage to cellular DNA from particulate radiations, the efficacy of its processing and the radiosensitivity of mammalian cells. Emphasis on DNA double strand breaks and chromatin breaks. Radiation and Environmental Biophysics, 31(4), 257–277.CrossRefPubMed

112.

Amini P, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Cheki M, et al. Mechanisms for radioprotection by melatonin; can it be used as a radiation countermeasure? Curr Mol Pharmacol. 2018.

113.

Pokharel, S., Rasoul, S., Roks, A. J., van Leeuwen, R. E., van Luyn, M. J., Deelman, L. E., Smits, J. F., Carretero, O., van Gilst, W., & Pinto, Y. M. (2002). N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension., 40(2), 155–161.CrossRefPubMed

114.

Sharma, U., Rhaleb, N. E., Pokharel, S., Harding, P., Rasoul, S., Peng, H., & Carretero, O. A. (2008). Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. American Journal of Physiology. Heart and Circulatory Physiology, 294(3), H1226–H1232.CrossRefPubMed

115.

Rhaleb, N. E., Pokharel, S., Sharma, U., & Carretero, O. A. (2011). Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. Journal of Hypertension, 29(2), 330–338.CrossRefPubMedPubMedCentral

116.

Rhaleb, N. E., Pokharel, S., Sharma, U. C., Peng, H., Peterson, E., Harding, P., Yang, X. P., & Carretero, O. A. (2013). N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1beta-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflügers Archiv, 465(10), 1487–1495.CrossRefPubMed

117.

Liu, Y. H., D'Ambrosio, M., Liao, T. D., Peng, H., Rhaleb, N. E., Sharma, U., André, S., Gabius, H. J., & Carretero, O. A. (2009). N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. American Journal of Physiology. Heart and Circulatory Physiology, 296(2), H404–H412.CrossRefPubMed

118.

Grillon, C., Rieger, K., Bakala, J., Schott, D., Morgat, J. L., Hannappel, E., Voelter, W., & Lenfant, M. (1990). Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters, 274(1–2), 30–34.PubMed

119.

Lenfant, M., Grillon, C., Rieger, K. J., Sotty, D., & Wdzieczak-Bakala, J. (1991). Formation of acetyl-Ser-Asp-Lys-Pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4. Annals of the New York Academy of Sciences, 628, 115–125.CrossRefPubMed

120.

Lipshultz, S. E., Sanders, S. P., Goorin, A. M., Krischer, J. P., Sallan, S. E., & Colan, S. D. (1994). Monitoring for anthracycline cardiotoxicity. Pediatrics., 93(3), 433–437.PubMed

121.

Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., Oeffinger, K. C., Rosenthal, D. N., Sable, C. A., Sallan, S. E., Singh, G. K., Steinberger, J., Cochran, T. R., Wilkinson, J. D., & American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiolo. (2013). Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation., 128(17), 1927–1995.CrossRefPubMed

122.

Shankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., et al. (2008). Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics., 121(2), e387–ee96.CrossRefPubMed

123.

Fulbright, J. M. (2011). Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice, 2011.

124.

van Dalen, E. C., van den Brug, M., Caron, H. N., & Kremer, L. C. (2006). Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. European Journal of Cancer, 42(18), 3199–3205.CrossRefPubMed

125.

Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine, 351(2), 145–153.CrossRefPubMed

126.

Malik, A., Jeyaraj, P. A., Calton, R., Uppal, B., Negi, P., Shankar, A., Patil, J., & Mahajan, M. K. (2016). Are biomarkers predictive of anthracycline-induced cardiac dysfunction? Asian Pacific Journal of Cancer Prevention, 17(4), 2301–2305.CrossRefPubMed

127.

Landier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., Freeman, C. R., Friedman, D. L., Green, D. M., Marina, N., Meadows, A. T., Neglia, J. P., Oeffinger, K. C., Robison, L. L., Ruccione, K. S., Sklar, C. A., & Hudson, M. M. (2004). Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. Journal of Clinical Oncology, 22(24), 4979–4990.CrossRefPubMed

128.

Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of Clinical Oncology, 30(10), 1042–1049.CrossRefPubMedPubMedCentral

129.

Zhang, C. J., Pei, X. L., Song, F. Y., Guo, Y., Zhang, Q. L., Shu, X. H., et al. (2017). Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT., 34(11), 1593–1600.

130.

Lipshultz, S. E., Landy, D. C., Lopez-Mitnik, G., Lipsitz, S. R., Hinkle, A. S., Constine, L. S., et al. (2012). Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Journal of Clinical Oncology, 30(10), 1050–1057.CrossRefPubMedPubMedCentral

131.

Leger, K. J., Leonard, D., Nielson, D., de Lemos, J. A., Mammen, P. P., & Winick, N. J. (2017). Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. Journal of the American Heart Association, 6(4), e004653.CrossRefPubMedPubMedCentral

132.

Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 23(Suppl 7:vii), 155–166.CrossRef

133.

Akam-Venkata, J., Franco, V. I., & Lipshultz, S. E. (2016). Late cardiotoxicity: issues for childhood cancer survivors. Current Treatment Options in Cardiovascular Medicine, 18(7), 47.CrossRefPubMed

134.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr., D. E., Colvin, M. M., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation., 136(6), e137–ee61.CrossRefPubMed

135.

Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre 2nd, V. C., Shaikh, S. L., Mone, S. M., et al. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology, 20(23), 4517–4522.CrossRefPubMed

136.

Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., Kimball, T. R., Delaat, C., Steinherz, L. J., & Zhao, H. (2004). Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology, 22(5), 820–828.CrossRefPubMed

137.

El-Shitany, N. A., Tolba, O. A., El-Shanshory, M. R., & El-Hawary, E. E. (2012). Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. Journal of Cardiac Failure, 18(8), 607–613.CrossRefPubMed

138.

Shakir, D. K., & Rasul, K. I. (2009). Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. Journal of Clinical Medical Research, 1(1), 8–12.

139.

Lipshultz, S. E., & Colan, S. D. (2004). Cardiovascular trials in long-term survivors of childhood cancer. Journal of Clinical Oncology, 22(5), 769–773.CrossRefPubMed

140.

Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine, 354(23), 2443–2451.CrossRefPubMed

141.

Hallas, J., Christensen, R., Andersen, M., Friis, S., & Bjerrum, L. (2012). Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. British Journal of Clinical Pharmacology, 74(1), 180–188.CrossRefPubMedPubMedCentral

142.

Ward, K. M., Binns, H., Chin, C., Webber, S. A., Canter, C. E., & Pahl, E. (2004). Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. The Journal of Heart and Lung Transplantation, 23(9), 1040–1045.CrossRefPubMed

143.

Bock, M. J., Pahl, E., Rusconi, P. G., Boyle, G. J., Parent, J. J., Twist, C. J., et al. (2017). Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: a report from the Pediatric Heart Transplant Study (PHTS) group. Pediatr Transplant, 21(5).

144.

Cox, C. L., Hudson, M. M., Mertens, A., Oeffinger, K., Whitton, J., Montgomery, M., & Robison, L. L. (2009). Medical screening participation in the childhood cancer survivor study. Archives of Internal Medicine, 169(5), 454–462.CrossRefPubMedPubMedCentral

Title: Cardiovascular diseases in survivors of childhood cancer
Authors: Neha Bansal
Javier G. Blanco
Umesh C. Sharma
Saraswati Pokharel
Shannon Shisler
Steven E. Lipshultz
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Cardiomyopathy
Radiotherapy
Anthracycline
Cytostatic Therapy
Published in: Cancer and Metastasis Reviews / Issue 1/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09859-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches

New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence

Professor Samuel C. Brooks, Jr., Ph.D. (1928–2019)

What are the effects of exercise training in childhood cancer survivors? A systematic review

Mouse models of high-risk neuroblastoma

Neurocognitive impairment in Asian childhood cancer survivors: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer